Matthew Klein
Amministratore Delegato presso PTC THERAPEUTICS, INC.
Patrimonio netto: 2 M $ in data 30/06/2024
Posizioni attive di Matthew Klein
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CLEARPOINT NEURO, INC. | Direttore/Membro del Consiglio | 16/04/2020 | - |
| Independent Dir/Board Member | 16/04/2020 | - | |
| PTC THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 22/03/2023 | - |
| Amministratore Delegato | 22/03/2023 | - | |
| Presidente | 22/03/2023 | - | |
| Direttore operativo | 07/01/2022 | 22/03/2023 | |
| Corporate Officer/Principal | 01/10/2019 | 07/01/2022 | |
| Stanford University | Corporate Officer/Principal | - | - |
| PTC Therapeutics International Ltd. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Matthew Klein
Precedenti posizioni note di Matthew Klein
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
BioElectron Technology Corp.
 BioElectron Technology Corp. Miscellaneous Commercial ServicesCommercial Services BioElectron Technology Corp. is a clinical-stage biotechnology company, which engages in the research and development of therapeutics for inherited mitochondrial disease. The company was founded in 2005 and is headquartered in Mountain View, CA. | Direttore/Membro del Consiglio | 01/01/2018 | 01/01/2020 |
| Amministratore Delegato | 01/01/2018 | 01/01/2019 | |
| Direttore Tecnico/Scientifico/R&S | 01/01/2012 | 01/01/2019 | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | Corporate Officer/Principal | - | - |
Edison Pharmaceuticals, Inc.
 Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edison Pharmaceuticals, Inc. developed drugs to treat mitochondrial diseases. It offers EPI-743 and EPI-A0001, an orally absorbed small molecules. The company was founded by Guy Miller in 2005 and was headquartered in Mountain View, CA. | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di Matthew Klein
| Yale University | Doctorate Degree |
| University of Pennsylvania | Undergraduate Degree |
| UW School of Public Health | Graduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 10 |
| Irlanda | 2 |
Posizioni
| Director/Board Member | 4 |
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
Settori
| Consumer Services | 6 |
| Health Technology | 4 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| CLEARPOINT NEURO, INC. | Health Technology |
| PTC THERAPEUTICS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Edison Pharmaceuticals, Inc.
Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edison Pharmaceuticals, Inc. developed drugs to treat mitochondrial diseases. It offers EPI-743 and EPI-A0001, an orally absorbed small molecules. The company was founded by Guy Miller in 2005 and was headquartered in Mountain View, CA. | Health Technology |
BioElectron Technology Corp.
BioElectron Technology Corp. Miscellaneous Commercial ServicesCommercial Services BioElectron Technology Corp. is a clinical-stage biotechnology company, which engages in the research and development of therapeutics for inherited mitochondrial disease. The company was founded in 2005 and is headquartered in Mountain View, CA. | Commercial Services |
| PTC Therapeutics International Ltd. |
- Borsa valori
- Insiders
- Matthew Klein
- Esperienza
